GenSight Biologics reported a second case of a patient with late-stage retinitis pigmentosa (RP) who partially recovered her visual function after treatment with GS030 optogenetic therapy. The GS030 optogenetic treatment, which combines gene therapy with the use of light-stimulating goggles, led to the patient being able to perceive and count objects one year after injection with GS030?s gene therapy component. The patient is a participant in the ongoing PIONEER Phase I/II clinical trial of GS030, like another patient whose partial recovery was published as a case report in Nature Medicine in May 2021. The patient, whose improvement is documented in a video, had been diagnosed with retinitis pigmentosa 20 years prior to enrollment and, at the time of injection, was barely able to perceive light. She received a single intravitreal (IVT) injection with the medium dose (1.5E11 vector genomes) of GS030 gene therapy in her worse-seeing eye and, after four months, started training on the use of the device. Twelve months after injection, the patient could detect and correctly locate objects of different sizes and contrasts placed on a white table in front of her, with a 57% success rate when wearing the GenSight light-stimulating goggles, compared to only 24% without the device.